Reclast is a once-yearly infusion that slows bone loss by shutting down the cells responsible for breaking down bone. Its active ingredient, zoledronic acid, belongs to a class of drugs called bisphosphonates, and it works at the molecular level to shift the balance between bone breakdown and bone building in your favor. Here’s what actually happens inside your body when you receive it.
What Reclast Does Inside Your Bones
Your skeleton is constantly remodeling itself. Specialized cells called osteoclasts dissolve old bone, while other cells called osteoblasts lay down new bone in its place. In osteoporosis, osteoclasts outpace osteoblasts, and you lose bone faster than you can replace it. Reclast targets the osteoclasts directly.
After the infusion enters your bloodstream, zoledronic acid travels to your bones and binds to the mineral surface, concentrating at sites where bone is actively being broken down. When osteoclasts arrive to dissolve bone in those areas, they absorb the drug. Once inside the cell, zoledronic acid blocks a specific enzyme that osteoclasts need to function and survive. Without this enzyme, the cell can’t produce certain molecules required for it to anchor to bone, maintain its structure, or send internal survival signals. The osteoclast essentially loses the ability to do its job.
The disruption triggers two separate kill switches. First, blocking the enzyme cuts off the production of signaling molecules that keep the cell alive. Second, a byproduct accumulates inside the osteoclast that interferes with its energy production, pushing the cell toward programmed death (apoptosis). The net result: fewer active osteoclasts, less bone resorption, and a gradual increase in bone density over time.
How Well It Prevents Fractures
Clinical trials have shown meaningful fracture reduction across multiple skeletal sites. Vertebral fractures, the most common type in osteoporosis, dropped by 46% to 77%. Hip fractures fell by 30% to 41%, and fractures at other non-spine locations decreased by 25% to 27%. These reductions reflect the drug’s ability to preserve bone density and maintain structural integrity in areas most vulnerable to osteoporotic breaks.
What the Infusion Looks Like
Reclast is given as a single 5 mg intravenous infusion, delivered over at least 15 minutes, once a year for osteoporosis. You don’t take a daily pill or give yourself an injection at home. The infusion is typically done at a doctor’s office, clinic, or infusion center.
Before your appointment, you’ll need to drink at least two glasses of water in the hours leading up to the infusion. Staying well hydrated helps protect your kidneys, since the drug is cleared through them. Your doctor will also want to make sure your calcium and vitamin D levels are adequate beforehand. For postmenopausal women, that typically means getting about 1,200 mg of calcium and 400 to 800 IU of vitamin D daily through food or supplements. Any existing low calcium levels need to be corrected before the infusion, because Reclast can temporarily lower blood calcium further as it slows bone turnover.
Side Effects in the First Few Days
The most common reaction is a flu-like response that can start within the first 24 hours after infusion. Symptoms include fever, muscle aches, joint pain, headache, chills, and general fatigue. Body temperature typically peaks around 24 hours after the infusion and gradually returns to normal over about 72 hours. For most people, these symptoms resolve within one to three days of appearing.
This reaction is more common after the first infusion and tends to be milder or absent with subsequent yearly doses. Over-the-counter pain relievers like acetaminophen or ibuprofen can help manage the discomfort. It’s worth planning a low-key day or two after your first infusion in case you feel run down.
Rare but Serious Risks
Two rare complications get the most attention with long-term bisphosphonate use: osteonecrosis of the jaw and atypical femur fractures.
Osteonecrosis of the jaw is a condition where a section of jawbone loses its blood supply and begins to deteriorate. In people taking bisphosphonates for osteoporosis, it occurs in roughly 1 in 10,000 to 1 in 100,000 patients. The risk is far higher in cancer patients receiving much larger and more frequent doses of similar drugs, so the numbers for osteoporosis patients are very low. Dental extractions and invasive jaw procedures increase the risk, which is why your doctor may recommend completing major dental work before starting treatment.
Atypical femur fractures are stress fractures that occur in an unusual location along the thighbone, often with minimal trauma. These are estimated at about 1.8 per 100,000 person-years in patients treated for two years, but the risk climbs with prolonged use, reaching roughly 113 per 100,000 person-years in patients who have been on bisphosphonates for eight to ten years. This is one reason doctors often reassess the need for continued treatment after three to five years.
Who Should Not Receive It
Reclast is not appropriate for people with severe kidney impairment, specifically a creatinine clearance of 35 mL/min or below. The drug is processed through the kidneys, and impaired function raises the risk of kidney damage. It’s also contraindicated if you have low blood calcium that hasn’t been corrected, or if you have certain mineral metabolism disorders related to parathyroid function or intestinal absorption issues.
Your doctor will typically check kidney function and calcium levels with a blood test before scheduling the infusion. If your kidneys are borderline, they may recommend a different osteoporosis treatment that doesn’t carry the same renal risk.
Why Once a Year Is Enough
The reason Reclast works on an annual schedule, unlike daily or weekly oral bisphosphonates, comes down to how tightly it binds to bone. Zoledronic acid has a very strong affinity for the mineral surface of bone, and once it’s embedded there, it stays for a long time. The drug is released slowly as bone naturally turns over, continuing to be taken up by osteoclasts for months. This creates a sustained effect from a single dose that other bisphosphonates, which bind less tightly or are less potent, can’t match. For many people, the convenience of one infusion per year also removes the daily or weekly compliance challenges that come with oral medications.